Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles G Drake

Showing results (51-60 of 266) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I Rini
Nature Reviews. Clinical Oncology|November 20, 2013
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancerCharles G Drake, Evan J Lipson, Julie R Brahmer
Current Oncology Reports|August 19, 2018
Immunotherapy in Prostate Cancer: Teaching an Old Dog New TricksMichael C Comiskey, Matthew C Dallos, Charles G Drake
Journal of Immunology (Baltimore, Md. : 1950)|January 10, 2018
Inhibitors of the PD-1 Pathway in Tumor TherapyMartin W LaFleur, Yuki Muroyama, Charles G Drake, et al.
The Lancet. Oncology|October 5, 2015
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergyAndrew B Sharabi, Michael Lim, Theodore L DeWeese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2015
New Strategies in Bladder Cancer: A Second Coming for ImmunotherapyAli Ghasemzadeh, Trinity J Bivalacqua, Noah M Hahn, et al.
Urologic Oncology|March 1, 2016
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overviewAngela K B Alme, Beerinder S Karir, Bishoy M Faltas, et al.
Biomed Research International|December 11, 2013
Immune modulation and stereotactic radiation: improving local and abscopal responsesJing Zeng, Timothy J Harris, Michael Lim, et al.
Oncoimmunology|November 22, 2012
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any moreMeghan E Turnis, Alan J Korman, Charles G Drake, et al.
Immunological Reviews|March 5, 2017
LAG3 (CD223) as a cancer immunotherapy targetLawrence P Andrews, Ariel E Marciscano, Charles G Drake, et al.
Pageof 27

Showing results (51-60 of 266) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I Rini
Nature Reviews. Clinical Oncology|November 20, 2013
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancerCharles G Drake, Evan J Lipson, Julie R Brahmer
Current Oncology Reports|August 19, 2018
Immunotherapy in Prostate Cancer: Teaching an Old Dog New TricksMichael C Comiskey, Matthew C Dallos, Charles G Drake
Journal of Immunology (Baltimore, Md. : 1950)|January 10, 2018
Inhibitors of the PD-1 Pathway in Tumor TherapyMartin W LaFleur, Yuki Muroyama, Charles G Drake, et al.
The Lancet. Oncology|October 5, 2015
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergyAndrew B Sharabi, Michael Lim, Theodore L DeWeese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2015
New Strategies in Bladder Cancer: A Second Coming for ImmunotherapyAli Ghasemzadeh, Trinity J Bivalacqua, Noah M Hahn, et al.
Urologic Oncology|March 1, 2016
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overviewAngela K B Alme, Beerinder S Karir, Bishoy M Faltas, et al.
Biomed Research International|December 11, 2013
Immune modulation and stereotactic radiation: improving local and abscopal responsesJing Zeng, Timothy J Harris, Michael Lim, et al.
Oncoimmunology|November 22, 2012
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any moreMeghan E Turnis, Alan J Korman, Charles G Drake, et al.
Immunological Reviews|March 5, 2017
LAG3 (CD223) as a cancer immunotherapy targetLawrence P Andrews, Ariel E Marciscano, Charles G Drake, et al.
Pageof 27